New cell therapy takes aim at Hard-to-Treat blood cancers
NCT ID NCT07628582
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new treatment called LVIVO-TaVec122 in 48 adults with B-cell blood cancers that have come back or not responded to standard therapy. The main goals are to check safety, find the right dose, and measure how long the treatment lasts in the body. It is an open-label study, meaning everyone knows they are getting the experimental therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, 210029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time infusion of Dual-Target CAR-T cells outsmart resistant blood cancers?
- Can a new pill outsmart Treatment-Resistant blood cancer?
- Supercharged immune cells take on tough lymphoma
- Experimental Dual-Target CAR-T therapy enters human testing for tough blood cancers
- Engineered immune cells take on tough blood cancers in new trial
- New injection aims to control tough blood cancers in early trial